ArticleMolecular neurobiology2026
Serum Vitamin E Levels in Multiple Sclerosis: Association with Diagnosis, Cognitive Function, Disability, and Depressive Symptoms.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system and the most common neurodegenerative disease in young adults, characterized by motor, sensory, visual, and cognitive impairments. Vitamin E (α-Tocopherol), a fat-soluble antioxidant, may influence cognitive function, disability, and mood in MS. One hundred eighty-four Italian Caucasian MS patients and ninety-four healthy controls were included. Clinical and demographic variables were recorded, and serum vitamin E levels were measured by HPLC. Cognitive function was assessed using the Mini-Mental State Examination (MMSE), disability with the Expanded Disability Status Scale (EDSS), and depressive symptoms with the Hamilton Depression Rating Scale (HDRS). Logistic and linear regression analyses were performed, adjusting for demographic, MS-related, and metabolic confounders. Bonferroni correction was applied. Discriminative ability for clinical cut-offs (MMSE ≤ 24, EDSS ≥ 6, HDRS ≥ 8) was assessed using receiver operating characteristic (ROC) curves. MS patients had significantly lower serum vitamin E levels compared to controls. Lower vitamin E levels were associated with MS diagnosis. In MS patients, higher vitamin E levels were associated with better cognitive performance and lower disability. All associations remained significant after Bonferroni correction in fully adjusted models. No significant relationship was found between vitamin E levels and depressive symptoms. Vitamin E showed good discriminative ability. Serum vitamin E levels showed significant associations with MS diagnosis, cognitive function, and disability, with good discriminative ability. Longitudinal studies are needed to clarify whether low vitamin E levels influence the risk of developing MS, while randomized controlled trials are warranted to determine whether vitamin E supplementation may provide clinical benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.